{
    "nct_id": "NCT02599454",
    "official_title": "A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically proven stage I NSCLC =< 5 cm diameter\n* One or more high-risk features identified:\n\n  * Tumor diameter >= 2 cm\n  * Tumor standardized uptake value maximum (SUVmax) >= 6.2\n  * Moderately, poorly differentiated or undifferentiated histology\n* Evaluable disease per RECIST 1.1\n* Patients must be medically or surgically inoperable as determined by a physician OR unwilling to undergo surgical resection\n* All patients must have an forced expiratory volume in 1 second (FEV1) >= 700cc\n* All patients must have a carbon monoxide diffusing capability test (DLCO) >= 5.5 m/min/mmHg\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2\n* Life expectancy >= 12 months\n* Absolute neutrophil count (ANC) > 1500 cells/uL\n* White blood cell count (WBC) > 2500/uL\n* Lymphocyte count > 500/uL\n* Platelet count > 100,000/uL\n* Hemoglobin > 9 g/dL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN\n* Serum bilirubin =< 1.0 x ULN\n* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) < 1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to enrollment)\n* Creatinine clearance > 30 mL/min by Cockcroft-Gault formula\n* No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)\n* No other active malignancy\n* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible\n* Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible\n* Archival tumor sample available; tissue from an fine-needle aspiration (FNA) is allowed but tumor tissue from a core needle biopsy is preferred\n* For female patients of childbearing potential and male patients with partners of childbearing potential agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of MPDL3280A\n* Signed informed consent\n* Ability to comply with the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled concomitant disease\n* Significant cardiovascular disease (New York Heart Association Class [NYHA] class II or greater); myocardial infarction within 3 month prior to randomization, unstable arrhythmias, unstable angina or a patient with a known left ventricular ejection fraction (LVEF) < 40%\n* Severe infection within 4 weeks prior to enrollment\n* Active tuberculosis\n* Oral or IV antibiotics within 2 weeks or 5 half-lives prior to enrollment\n* History of autoimmune disease\n* Positive for human immunodeficiency virus (HIV), hepatitis B (hepatitis B surface antigen [HBsAg] reactive), or hepatitis C virus (hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected)\n* History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia\n* Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrollment\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications within past 4 weeks or 5 half-lives whichever is shorter\n* Pregnant and/or lactating women",
    "miscellaneous_criteria": ""
}